Company Overview and News

17
A $6 Billion China Startup Wants to Be the Amazon of Health Care - Bloomberg

2018-07-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
0017 SFOSF BABA NWSGY 0659 0700 AAGIY GSK BIDU GSK NWSZF AAIGF

17
WeDoctor, a $6 billion China startup, wants to be the Amazon of health care

2018-07-03 livemint
Hong Kong: As soon as you’re diagnosed as diabetic, ads for treatments show up on social feeds. You get alerts on health supplements, maybe nutrition tips. Prompts on insurance policies pop up on your phone.
0017 SFOSF BABA NWSGY 0659 0700 AAGIY GSK BIDU GSK NWSZF AAIGF

1
Aging Hong Kong Waterfront Gets a Face-Lift - The New York Times

2018-06-27 nytimes
The $2.6 billion Victoria Dockside will be a modern art and design district, its developer says, combining retail, residential and commercial interests.
0017 NYTAB

0
Rich millennials target of ultra high-end museum-retail space set to open in HK

2018-06-24 lifestyle.inquirer.net
A major $2.6 billion development that’s been called “Hong Kong’s Hudson Yards” and makes no qualms about its aim to specifically attract wealthy millennials now has a name and an opening timeframe: K11 Musea will open in the fall of 2019.
0017

0
Hong Kong stock market slump spurs wave of insider share buying among blue chips

2018-06-24 scmp
Hang Seng Index constituents CK Asset Holdings, Sun Hung Kai Properties, New World Development and Hopewell Holdings all recorded buying by company insiders or corporate share buy-backs for the holiday-shortened week of June 19 to 22 as Hong Kong’s stock market fell 3.2 per cent for the period
SUHJY 0017 0016 SHGKF SHGKY HOWWF HOWWY SUHJF 0054

0
Home demand helps developers clear housing stock before Hong Kong slaps vacancy tax on hoarders

2018-06-23 scmp
Hong Kong’s property buyers braved a thunderstorm to snap up more than a hundred unoccupied apartment units, helping developers clear the unsold stock ahead of a government plan to impose a so-called vacancy tax to deter hoarding.
SUHJY 0017 0016 SHGKF SHGKY 0012 SUHJF

0
Hong Kong developers rush to sell empty flats ahead of new vacancy tax

2018-06-20 scmp
Government is due to discuss details of a new levy on vacant properties as a way of helping ease the city’s acute housing shortage
SUHJY 0017 0016 SHGKF SHGKY MTRJY SUHJF

0
Lai Chi Kok – Hong Kong’s version of Dongdaemun and Camden Market for fashion start-ups

2018-06-20 scmp
It appears that most major cities in the world have a market hub for budding entrepreneurs. London has Camden Market, Seoul has Dongdaemun Market and Melbourne has the Jam Factory. Now Hong Kong has it own as the old factory district of Lai Chi Kok is evolving into a start-up hub for fashion designers.
0017

0
How much longer will Hong Kong remain a laggard in green buildings?

2018-06-19 scmp
The city is one the world’s least and most green cities – only a fraction of 40,000 buildings are green but over 75pc of land has been left in a relatively natural state
SUHJY 0017 0016 SHGKF 1972 SWROY SHGKY SWPFF 0083 SUHJF

0
Hong Kong companies have much to do to improve their dismal green credentials

2018-06-12 scmp
Panellists at the ‘Redefining Hong Kong Debate Series’ urge companies to implement changes to become sustainable and environmentally and socially responsible
0017

0
Fear of interest rates hike, high prices, hit latest property sale

2018-06-12 scmp
But still, three projects alone have pulled in US$1.46 billion worth of sales released in the past fortnight
0017 0050 0012

0
Gen-Zs in their 20s are fastest-growing group of loan borrowers, spurred by cheap and easy money

2018-06-10 scmp
Generation Z, the section of the population born in the mid-90s, was the fastest-growing segment of borrowers in Hong Kong during the first quarter, according to data by the credit report company TransUnion.
0017

1
Hong Kong tycoon Henry Cheng shrugs off retirement rumours at Chow Tai Fook results announcement

2018-06-07 scmp
Net profit at world’s largest listed jeweller by market value amounts to HK$4.1 billion, misses analysts’ forecast of 36.3 per cent
0017 1929

0
Chinese diabetes drug maker Hua Medicine becomes second firm to seek Hong Kong listing under new bourse rules

2018-06-06 scmp
Chinese diabetes drugs developer Hua Medicine has become the second firm to apply to list in Hong Kong after the exchange changed its rules to allow biotechnology firms with no revenue to join as a way of attracting more listings.
0017

0
Homebuyers ignore 10pc price hike, snap up 100-plus units at luxury North Point development

2018-06-06 scmp
A luxury residential development in North Point drew a strong response from buyers on Wednesday, with more than 100 units snapped up by early afternoon, even as prices at New World Development’s Fleur Pavilia were bumped up by 10 per cent from those sold a week earlier.
0017

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...